ACS Chem Neurosci:基于咖啡因的新型化合物或可有效抵御帕金森疾病

2016-10-05 佚名 生物谷

图片来源:medicalxpress.com 近日,一项刊登于国际杂志ACS Chemical Neuroscience上的研究报告中,来自萨斯喀彻温大学(University of Saskatchewan)的研究人员通过研究开发出了两种基于咖啡因的化合物,这种新型化合物或可有效帮助抵御帕金森疾病对患者的影响。 帕金森疾病能够攻击机体的神经系统,诱发患者不受控制的颤抖、肌肉僵硬、运动缓慢

图片来源:medicalxpress.com

近日,一项刊登于国际杂志ACS Chemical Neuroscience上的研究报告中,来自萨斯喀彻温大学(University of Saskatchewan)的研究人员通过研究开发出了两种基于咖啡因的化合物,这种新型化合物或可有效帮助抵御帕金森疾病对患者的影响。

帕金森疾病能够攻击机体的神经系统,诱发患者不受控制的颤抖、肌肉僵硬、运动缓慢、不精确的运动,尤其是中老年患者;帕金森疾病的引发是由大脑中缺失产生多巴胺的脑细胞而引起,多巴胺是一种重要的神经递质,其能够促进神经元间互相“交流”。文章中,研究者重点对一种名为α-突触核蛋白(α-synuclein,AS)进行研究,该蛋白能够参与多巴胺的调节。

在帕金森患者机体中,α-突触核蛋白会发生错误折叠形成致密的结构,而这种致密结构和产生多巴胺的神经元的死亡直接相关,更为严重的是,α-突触核蛋白似乎能够表现地像引发朊病毒病的朊病毒一样,在朊病毒病中,错误折叠的蛋白质就能够诱发其它蛋白的错误折叠,从而就像倒了的多米诺骨牌一样,促使疾病进展。

研究者Lee表示,当前很多治疗性的化合物都主要关注于增强残存细胞的多巴胺输出,但这仅仅在由足够细胞发挥作用的情况下才是有效的,而我们的研究目的就是通过抑制α-突触核蛋白的错误折叠来保护产生多巴胺的神经元细胞;尽管面临着巨大挑战,研究者们通过研究合成了30种不同的双功能二聚体药物,也就是说,这些药物分子连接着两种不同的物质,而这些物质对于产生多巴胺的细胞具有一定的效应;随后研究人员以咖啡因“支架”开始进行研究,随后他们发现了一种刺激物具有明显保护机体抵御帕金森疾病的效应,以咖啡因“支架”为基础,研究者逐渐添加上了具有多种效应的其它化合物,比如尼古丁、二甲双胍、氨基茚等,同时研究者们还探索了和帕金森药物雷沙吉兰类似的化学效应。

利用帕金森疾病酵母模型,研究者Lee及其研究团队发现了两种化合物能够抑制α-突触核蛋白的聚集,从而就会有效地使得细胞正常生长。最后研究者Lee表示,我们的研究结果表明,这些新型的双功能二聚体化合物分子或许在抑制帕金森疾病的进展上扮演着重要的作用,后期我们还将通过更为深入的研究来开发治疗帕金森疾病的新型疗法。

原始出处

Joe Kakish, Kevin J.H. Allen, Troy A. Harkness, Edward Stanley Krol, and Jeremy Stuart Lee.Novel Dimer Compounds That Bind α-Synuclein Can Rescue Cell Growth in a Yeast Model Overexpressing α-Synuclein. A Possible Prevention Strategy for Parkinson’s Disease.ACS Chem Neurosci.2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
    2016-10-07 yaanren
  4. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
    2016-10-07 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
    2016-10-06 医路开来

    謝謝分享。,,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
    2016-10-06 医路开来

    學習啦,,,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1906323, encodeId=5d991906323df, content=<a href='/topic/show?id=7795334e220' target=_blank style='color:#2F92EE;'>#化合物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33472, encryptionId=7795334e220, topicName=化合物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Mon Feb 13 00:18:00 CST 2017, time=2017-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263929, encodeId=ed8012639294c, content=<a href='/topic/show?id=62c239e74f2' target=_blank style='color:#2F92EE;'>#咖啡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39774, encryptionId=62c239e74f2, topicName=咖啡因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=316c73, createdName=caoliehu, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279133, encodeId=3da712e91334d, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364128, encodeId=fca41364128ae, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406649, encodeId=798c1406649f5, content=<a href='/topic/show?id=ae2e4851879' target=_blank style='color:#2F92EE;'>#帕金森疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48518, encryptionId=ae2e4851879, topicName=帕金森疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1f002566823, createdName=guguangxiang, createdTime=Fri Oct 07 06:18:00 CST 2016, time=2016-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141067, encodeId=8beb14106e6a, content=謝謝分享。,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:48 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141066, encodeId=dd9c1410667c, content=學習啦,,,, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:43 CST 2016, time=2016-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141065, encodeId=7f9614106508, content=帕金森药物雷沙吉兰类似的化学效应。, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfdY7yem1P7bRvOP6z0jKsBoYR8ezfAricY7meQWcte7LRJsWHVn0CnPJg2JuQmevR0DoFmmEib5QLD2kNESBESQT/0, createdBy=59191706502, createdName=医路开来, createdTime=Thu Oct 06 14:19:30 CST 2016, time=2016-10-06, status=1, ipAttribution=)]
    2016-10-06 医路开来

    帕金森药物雷沙吉兰类似的化学效应。

    0

相关资讯

你全身上下都有哪些微生物,这个人都可以给你画出来

皮特·德利斯特恩的方法能够揭示微生物在复杂群落中的作用与功能。图片来源:Sandy Huffaker 除了一张跑步机办公桌,皮特·德利斯特恩(Pieter Dorrestein)在加利福尼亚大学圣迭戈分校(UCSD)的办公室并没有什么特别:一张圆形工作台周围摆满了椅子,书架上满是期刊、论文和书籍,还有许多表彰他个人及其工作的奖章。 但一旦他开始给来访者演示他的工作,

Sleep:睡眠不足,狂喝咖啡也没什么卵用

一项新的研究发现,如果控制民众睡眠时间,要求民众睡5个小时/晚并持续3天,则咖啡因的使用也不能提高民众的警觉性和工作效率。研究发表在Sleep。结果表明,相对于安慰剂,实验组民众饮用咖啡因后可显著提高精神、运动能力、警觉性、工作效率,但是仅维持2天。 该研究为一项双盲、安慰剂对照研究,参与者为48名体质健康的成人。在实验条件下,他们连续5日限制睡眠,每日睡眠时长为5小时。实验组民众每日两次服用20

提神醒脑的能量饮料真的安全吗?

尽管有报道称能量饮料可能造成健康隐患,但是其销量还是稳步上升。在2008年到2012年间,美国能量饮料的销量增加了60%,据估计到2017年美国能量饮料的年销售额将超过210亿美元。多数能量饮料的主要成分是咖啡因:部分饮料最多含有500mg咖啡因,相当于4到5杯咖啡的量。能量饮料中可能还有糖、瓜拉那、牛磺酸、西洋参成分、维生素、葡糖醛酸内酯以及其他成分。各种能量饮料品牌纷纷打出提神,增强体力和脑力

Sci Rep:咖啡因及其类似物或可逆转记忆丧失

在一项新的研究中,来自葡萄牙分子医学研究所和法国国家健康与医学研究院等机构的研究人员揭示出咖啡因抵抗动物体内年龄相关性认知缺陷的机制。相关研究结果于2016年8月11日在线发表在自然出版集团旗下的Scientific Reports期刊上,论文标题为“The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysf

咖啡是天使,还是魔鬼?

在睡眼惺忪的早晨,或是慵懒小困的午后,很多人会选择来一杯咖啡提提神。每当路过街角的咖啡店,也常常会被咖啡那难以抗拒的醇厚香气引诱进去。据了解,美国2015年一年内在咖啡上面的消费达到了742亿美元,咖啡在美国的广泛性甚至高于自来水。2014年,全球范围内售出的60千克包装咖啡超过1.5亿份。咖啡已经是当之无愧的大众饮品。 有人喝了咖啡之后神清气爽,精力充沛,思想集中,感觉还能再工作五百年

看一下成分!“失身酒”在美国出过多起人命,在中国却一路畅销!

important; word-wrap: break-word !important;">看不懂你起码查一下单词啊,哪怕 P 一下图再上架呢。12% 的酒精 + 咖啡因,真的是想搞大新闻吗?再想想,即使改良了,为什么在美国还是没什么人买?因为大家知道这酒背负着许多年轻的生命。而且,即使你改良了,这酒是会真出事的。咖啡因+兴奋剂+酒精的效果,如果多来两瓶,尤其是胖一点的人,很可能已经不省人事了。难